Sat.Oct 21, 2023 - Fri.Oct 27, 2023

article thumbnail

Leveraging real-world evidence with analytics: 3 essential components to capture a 360-degree view of your patient population

Bio Pharma Dive

Three essential components to create impactful real-world evidence with a 360-degree patient journey.

290
290
article thumbnail

FDA cracks down on off-label drug use messaging

Pharmaceutical Technology

The FDA released a draft guidance giving firms recommendations on provider-directed communication for off-label drug use.

Drugs 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma dips toe into tech adoption, but is it deep enough?

pharmaphorum

Pharma dips toe into tech adoption, but is it deep enough? Mike.

59
article thumbnail

Bristol Myers says new drugs sales will grow more slowly

Bio Pharma Dive

Company shares fell Thursday as the company adjusted its medium-term guidance for sales of new products like Reblozyl, Camzyos and Abecma.

Sales 182
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Pear Therapeutics: a lesson for future DTx developers

Pharmaceutical Technology

Pear Therapeutics was a pioneer in developing DTx for neurological conditions traditionally treated by evidence-based behavioural or psychological management strategies.

article thumbnail

The longitudinal history of medicines innovation: Part One

pharmaphorum

The longitudinal history of medicines innovation: Part One Mike.

Medicine 115

More Trending

article thumbnail

Verve gets FDA green light to run base editing study in US

Bio Pharma Dive

The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S. since late last year as the FDA sought more details on Verve’s in vivo treatment for heart disease.

In-Vivo 344
article thumbnail

What Challenges Is the Vaccine Industry Facing When Dealing with the Flu and COVID-19?

XTalks

Fall marks the beginning of the “flu season,” the period during the year when influenza (flu) viruses are in increased circulation and cause illness at higher rates than usual. The season also marks the increased circulation of other respiratory viruses, including SARS-CoV-2, which causes COVID-19, and respiratory syncytial virus (RSV). In the US, the flu or respiratory virus season typically begins in the fall and peaks in the winter, usually between December and February, but it can last as la

Vaccine 105
article thumbnail

5 things to look for in a marketing analytics partner

Bio Pharma Dive

Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.

Marketing 279
article thumbnail

ADDF announces speech database to identify biomarkers for Alzheimer’s

Pharmaceutical Technology

SpeechDx will contain recorded voice samples and other data, which will be used to develop algorithms for creating new speech biomarkers.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

New Link Between Fungal Organisms And Severe COVID Discovered

AuroBlog - Aurous Healthcare Clinical Trials blog

Many tiny organisms including bacteria, fungi and viruses normally live on our bodies, and even inside us. These are called the microbiome. The large number of these organisms living in the gastrointestinal tract are collectively known as the gut microbiome.

Bacteria 245
article thumbnail

Local authorities in England are failing to meet dementia diagnosis targets

Pharma Times

The APPG has called for urgent improvements in rural and ethnically diverse-areas - News - PharmaTimes

155
155
article thumbnail

Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs

Bio Pharma Dive

In a wide-ranging interview, Bristol Myers’ Ken Rhodes talked biomarkers, diseases of interest and why the company is far from done with neuroscience-focused deals.

Research 316
article thumbnail

UK NICE recommends use of AbbVie’s Parkinson’s treatment 

Pharmaceutical Technology

The UK NICE has recommended the use of AbbVie’s foslevodopa–foscarbidopa (Produodopa) for the treatment of advanced Parkinson’s disease.

246
246
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Adults With ADHD at Greater Risk of Dementia, Study Shows

AuroBlog - Aurous Healthcare Clinical Trials blog

Adults diagnosed with attention-deficit/hyperactivity disorder ( ADHD) are almost three times more likely to go on to develop dementia, according to a new study that looked at 109,218 adults with and without the condition over a period of 17 years. The researchers, from institutions in Israel and the US, found that 13.

Research 238
article thumbnail

NHS virtual wards to treat heart failure patients at home

Pharma Times

Thousands of patients with heart failure are set to benefit from the expansion - News - PharmaTimes

149
149
article thumbnail

OrbiMed raises $4.3B in new funds for startup investing

Bio Pharma Dive

The money will be spread across three investment funds and comes at a time when investment into biotech remains shakier than in years past.

317
317
article thumbnail

(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval

Pharmaceutical Technology

(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

The Brain Cells That Give You Motion Sickness May Have Been Identified

AuroBlog - Aurous Healthcare Clinical Trials blog

If the idea of driving down a winding road makes you feel queasy, spare a thought for the mice employed in a new study, which sought to pinpoint the brain cells responsible for motion sickness.

Research 231
article thumbnail

AstraZeneca granted licence for Nanoform’s AI technology

Pharma Times

STARMAP will accelerate the selection of AZ’s best molecule candidates - News - PharmaTimes

149
149
article thumbnail

Pfizer wins FDA approval of new meningococcal vaccine

Bio Pharma Dive

The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.

article thumbnail

How gene therapies can transform sickle cell disease treatment

Pharmaceutical Technology

The potential for using gene therapies to treat sickle cell disease is high, but their durability and high price point invite scrutiny.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

ICMR invites proposals to establish Ayush-ICMR Advanced Centre for Integrative Health Research at AIIMS

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian Council of Medical Research (ICMR) has invited proposals to establish Ayush-ICMR Advanced Centre for Integrative Health Research (AI-ACIHR) at the All India Institute of Medical Sciences (AIIMS) under Extramural Programme. This is following a Memorandum of Agreement (MoA) signed between the Union Ministry of Ayush and the ICMR at an inter-ministerial level.

Research 189
article thumbnail

Parkinson’s UK awards over £1.8m for nine research projects

Pharma Times

Around 145,000 people in the UK are living with Parkinson’s disease - News - PharmaTimes

Research 144
article thumbnail

Aiolos Bio raises $245M on prospect of better asthma drug

Bio Pharma Dive

The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.

Protein 317
article thumbnail

Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies

Pharmaceutical Technology

The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport

Drugs 246
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

NABH releases first edition of NABH Certification standards for stroke care centres

AuroBlog - Aurous Healthcare Clinical Trials blog

The National Accreditation Board for Hospitals and Healthcare Providers (NABH) has released the first edition of NABH Certification standards for stroke care centres. It has urged all the centres across the country to apply for accreditation depending on the self-assessment of the standards.

article thumbnail

FDA grants clearance for Endogena’s age-related macular degeneration treatment

Pharma Times

The company will launch a clinical investigation of EA-2351 for geographic atrophy - News - PharmaTimes

144
144
article thumbnail

Vertex gearing up for launch as sickle cell therapy review advances

Bio Pharma Dive

Executives at the biotech say they’re trying to get ahead of the payer and production challenges that will face their gene editing treatment exa-cel, which is now under FDA review.

article thumbnail

(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval

Pharmaceutical Technology

(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.